Ticker

DSNKY, LPX and RAL have been added to the Zacks Rank #5 (Strong Sell) List on February 25, 2026.

Daiichi Sankyo shares are potentially deeply undervalued, but the near-term outlook hinges on pivotal clinical trial outcomes, notably the AVANZAR study. Enhertu continues to grow well, and Datroway is off to a good start in breast cancer, but upcoming lung cancer readouts are critical for unlocking multi-billion-dollar revenue potential. Recent clinical delays, mixed pipeline results, and management's push toward a…

JONESBORO, Ark.--(BUSINESS WIRE)--SylamoreBio, a biotechnology company pioneering advanced therapeutic delivery to the central nervous system (CNS) and other recalcitrant tissues, today announced it has entered into a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute San Diego. The collaboration will leverage SylamoreBio's proprietary SyLEC delivery technology in…

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026. Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring…

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). The collaboration will integrate AI-driven translational intelligence into the core of an antibody drug conjugate (ADC) development program of Daiichi Sankyo to move beyond standard exploratory biomarker analysis and…